Chemists unlock new possibilities for rare-earth metal
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Oct-2026 19:17 ET (25-Oct-2026 23:17 GMT/UTC)
A University of Iowa-led chemistry team has isolated an atypical form of the rare-earth metal terbium – under normal environmental conditions. The breakthrough could make terbium and similar metals easier to separate and study, potentially expanding their use in quantum technologies, electronics, medicine, and other applications. Results published in the journal Nature Communications.
Invasive fungal infections induced by Candida species are becoming an urgent threat to global health. While a series of antifungal vaccines have been developed, their efficiency is frequently compromised by the failure of immune stimulation. In this study, a novel antifungal vaccine was constructed by assembling β-glucan with the Candida albicans antigen candidalysin on the surface of the genetically engineered Escherichia coli strain EcS. This co-assembly was mediated by the cell surface-exposed artificial glucan-binding protein CipC-mCherry-CipC, leading to the formation of the surface glucan nanofilm with a thickness of ~ 80 nm. Upon coincubation with macrophages, the vaccine efficiently escapes from the lysosomes, leading to enhanced production of reactive oxygen species (ROS) and macrophage maturation. After mouse immunization, the vaccine persists longer in lymph nodes than free candidalysin or the glucan-free complex, and induces higher levels of CD4+, CD8+, TNFα+/CD4+ and IFNγ+/CD4+ T cells in the spleen. In a murine model of invasive fungal infection,immunization with this vaccine remarkably increases the survival rate, reduces the kidney fungal burdens and attenuates inflammatory responses. This bioengineering strategy offers a potentially viable approach for developing co-assembled whole-cell vaccines and can be extended to leverage bacterial carriers for surface antigen display. The vaccine acts not only as antigens but also as adjuvants, thereby eliciting strong and specific protective immunity against invasive fungal infections.
The Lasker Foundation today announced the winners of its 2026 Lasker Awards: Emmanuel Mignot (Stanford University School of Medicine) and Masashi Yanagisawa (University of Tsukuba) will receive the Albert Lasker Basic Medical Research Award; Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa (Chugai Pharmaceutical) will receive the Lasker~DeBakey Clinical Medical Research Award; and Michael J. Fox (The Michael J. Fox Foundation for Parkinson’s Research) will receive the Lasker~Bloomberg Public Service Award.